Loading viewer...
investor_presentation
Format: PDF investor_presentation
Year End Results Presentation For the 12 months ended 30 June 2021
Year End Results Presentation
For the 12 months ended 30 June 2021DISCLAIMER
We may make statements that are not historical facts and relate to analyses and other information based on forecasts of futur e results and estimates of amounts
not yet determinable. These are forward looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as “prospects”,
“believe”, “anticipate”, “expect”, “intend”, “seek”, “will”, “plan”, “indicate”, “could”, “may”, “endeavour” and “project” an d similar expressions are intended to
identify such forward looking statements, but are not the exclusive means of identifying such statements. By their very natur e, forward -looking statements involve
inherent risks and uncertainties, both general and specific, and there are risks that predictions, forecasts, projections and other forward- looking statements will
not be achieved. If one or more of these risks materialise, or should underlying assumptions prove incorrect, actual results may be very different from those
anticipated. The factors that could cause our actual results to differ materially from the plans, objectives, expectations, e stimates and intentions expressed in such
forward -looking statements are discussed in each year’s annual report.
Forward looking statements apply only as of the date on which they are made, and we do not undertake other than in terms of t he Listings Requirements of the
JSE Limited, any obligation to update or revise any of them, whether as a result of new information, future events or otherwi se.Any profit forecasts published in
this report are unaudited and have not been reviewed or reported on by Aspen's external auditors.
2CAUTIONARY REGARDING FORWARD -LOOKING STATEMENTSDISCLOSURE NOTE
Discontinued European Business
The discontinued European business comprises the European Thrombosis Assets divested to Mylan until the date of disposal, bei ng 27 November 2020, the costs
relating to its disposal, related Thrombosis product discontinuations and other product divestments. The results of the disco ntinued European Business and the
residual costs relating to prior period disposals have been classified as discontinued operations in terms of IFRS 5 and have been reported separately in the
discontinued operations statement of comprehensive income including a restatement of comparative periods.
The prior year finance costs previously shown as attributable to discontinued operations have been reclassified to be include d in continuing operations. The
resultant restatement of the comparative numbers for continuing and discontinued operations is not material with the value of finance costs being reclassified
from discontinued to continuing operations for the prior comparative period amounting to R74 million.
The Group has revised its reportable segments to reflect the newly updated operating model which aligns to the way in which t he business is managed and
Preview truncated — download the full document for the complete content.
investor_presentation
39 Pages
investor_presentation
56 Pages
First Republic Bank
investor_presentation
Workiva
investor_presentation
Fraport